Statin use and cataract surgery: A nationwide retrospective cohort study in elderly ethnic Chinese patients

Drug Safety

Volumn 36, Issue 10, 2013, Pages 1017-1024

  Lai, Chao Lun ^a   Shau, Wen Yi ^b   Chang, Chia Hsuin ^a,c   Chen, Ming Fong ^a   Lai, Mei Shu ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Center for Drug Evaluation   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ARTICLE; CATARACT EXTRACTION; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TIME;

AGED; AGED, 80 AND OVER; CATARACT; CATARACT EXTRACTION; CHINA; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; TAIWAN;

EID: 84885462062     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0076-0     Document Type: Article

References (32)

1. Javitt JC, Wang F, West SK. Blindness due to cataract: epidemiology and prevention. Annu Rev Public Health. 1996;17:159-77.
2. West SK, Munoz B, Schein OD, et al. Racial differences in lens opacities: the Salisbury Eye Evaluation (SEE) project. Am J Epidemiol. 1998;148(11):1033-9.
3. Cheng CY, Liu JH, Chen SJ, et al. Population-based study on prevalence and risk factors of age-related cataracts in Peitou Taiwan. Chin Med J (Taipei). 2000;63(8):641-8.
4. Tsai SY, Hsu WM, Cheng CY, et al. Epidemiologic study of age-related cataracts among an elderly Chinese population in Shih-Pai Taiwan. Ophthalmology. 2003;110(6):1089-95.
5. Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exp Physiol. 2008;93(1):27-42.
6. Evans M, Roberts A, Davies S, et al. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Drugs. 2004;64(11):1181-96.
7. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78.
8. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.
9. Brown WV. Safety of statins. Curr Opin Lipidol. 2008;19(6):558-62.
10. Kiortsis DN, Filippatos TD, Mikhailidis DP, et al. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis. 2007;195(1):7-16.
11. Gerson RJ, MacDonald JS, Alberts AW, et al. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res. 1990;50(1):65-78.
12. Cenedella RJ. Cholesterol and cataracts. Surv Ophthalmol. 1996;40(4):320-37.
13. Laties AM, Shear CL, Lippa EA, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin. Am J Cardiol. 1991;67(6):447-53.
14. Chylack LT Jr, Mantell G, Wolfe JK, et al. Lovastatin and the human lens; results of a two year study. The MSDRL Study Group. Optom Vis Sci. 1993;70(11):937-43.
15. Harris ML, Bron AJ, Brown NA, et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. Br J Ophthalmol. 1995;79(11):996-1002.
16. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1996;156(18):2085-92.
17. Schlienger RG, Haefeli WE, Jick H, et al. Risk of cataract in patients treated with statins. Arch Intern Med. 2001;161(16):2021-6.
18. Smeeth L, Hubbard R, Fletcher AE. Cataract and the use of statins: a case-control study. QJM. 2003;96(5):337-43.
19. Klein BE, Klein R, Lee KE, et al. Statin use and incident nuclear cataract. JAMA. 2006;295(23):2752-8.
20. Tan JS, Mitchell P, Rochtchina E, et al. Statin use and the long-term risk of incident cataract: the Blue Mountains Eye Study. Am J Ophthalmol. 2007;143(4):687-9.
21. Chodick G, Heymann AD, Flash S, et al. Persistence with statins and incident cataract: a population-based historical cohort study. Ann Epidemiol. 2010;20(2):136-42.
22. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.
23. Machan CM, Hrynchak PK, Irving EL. Age-related cataract is associated with type 2 diabetes and statin use. Optom Vis Sci. 2012;89(8):1165-71.
24. Fong DS, Poon KY. Recent statin use and cataract surgery. Am J Ophthalmol. 2012;153(2):222-8.
25. National Health Insurance Research Database, Taiwan. http://w3.nhri.org. tw/nhird/en/index.htm.
26. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46(10):1075-9.
27. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
28. Levesque LE, Hanley JA, Kezouh A, et al. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.
29. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492-9.
30. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-81.
31. Mayne TJ, Whalen E, Vu A. Annualized was found better than absolute risk reduction in the calculation of number needed to treat in chronic conditions. J Clin Epidemiol. 2006;59(3):217-23.
32. Abraham AG, Condon NG, West Gower E. The new epidemiology of cataract. Ophthalmol Clin North Am. 2006;19(4):415-25.